Literature DB >> 15471176

Treatment of chronic hepatitis C patients not responding to combination therapy with ribavirin and interferon alpha--hype or hope?

Wolfgang Vogel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15471176      PMCID： PMC7088274          DOI： 10.1007/BF03217702

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN： 0043-5325            Impact factor:   1.704


× No keyword cloud information.
  15 in total

1.  Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine.

Authors:  Rudolf E Stauber; Harald Hofer; Franz Hackl; Kurt Schütze; Christian Datz; Karin Hegenbarth; Wolfgang Jessner; Petra Steindl-Munda; Ferenci Peter
Journal:  Wien Klin Wochenschr       Date:  2004-08-31       Impact factor: 1.704

Review 2.  Monitoring of viral levels during therapy of hepatitis C.

Authors:  Gary L Davis
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

3.  Antiviral drugs: current state of the art.

Authors:  E De Clercq
Journal:  J Clin Virol       Date:  2001-08       Impact factor: 3.168

4.  In vitro effect of amantadine and interferon alpha-2a on hepatitis C virus markers in cultured peripheral blood mononuclear cells from hepatitis C virus-infected patients.

Authors:  J Martín; S Navas; M Fernández; M Rico; M Pardo; J A Quiroga; F Zahm; V Carreño
Journal:  Antiviral Res       Date:  1999-05       Impact factor: 5.970

5.  Treatment of chronic hepatitis C with amantadine hydrochloride in patients who had not responded to previous treatment with interferon-alpha and/or ribavirin.

Authors:  V Di Martino; H Boudjema; T Delacour; A Cazier; C Caron; P Coutarel; P Dumouchel; J F Cadranel
Journal:  Clin Infect Dis       Date:  2001-02-28       Impact factor: 9.079

6.  Treatment of chronic hepatitis C with amantadine.

Authors:  J P Smith
Journal:  Dig Dis Sci       Date:  1997-08       Impact factor: 3.199

7.  Combination of interferon induction therapy and ribavirin in chronic hepatitis C.

Authors:  P Ferenci; H Brunner; K Nachbaur; C Datz; M Gschwantler; H Hofer; R Stauber; F Hackl; W Jessner; M Rosenbeiger; P Munda-Steindl; K Hegenbarth; A Gangl; W Vogel
Journal:  Hepatology       Date:  2001-11       Impact factor: 17.425

8.  Treatment of chronic hepatitis C with amantadine.

Authors:  J S Goff; R M Reveille; J Johnson
Journal:  Dig Dis Sci       Date:  2000-07       Impact factor: 3.199

9.  A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C.

Authors:  A Mangia; N Minerva; M Annese; G Leandro; M R Villani; R Santoro; V Carretta; D Bacca; A Giangaspero; M Bisceglia; F Ventrella; G Dell'Erba; A Andriulli
Journal:  Hepatology       Date:  2001-04       Impact factor: 17.425

10.  Randomized, double-blind, placebo-controlled trial of interferon alfa2a with and without amantadine as initial treatment for chronic hepatitis C.

Authors:  S Zeuzem; G Teuber; U Naumann; T Berg; J Raedle; S Hartmann; U Hopf
Journal:  Hepatology       Date:  2000-10       Impact factor: 17.425
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.